NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Gunnels Wood Road, Sbc,united Kingdom
- Phone
- 44 1438 906 960
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- nerretherapeutics.com
- Keywords
- jobs.
- HQ
- Stevenage, Hertfordshire
Nerre Therapeutics Ltd Questions
Nerre Therapeutics Ltd's helpline number is 44 1438 906 960
Nerre Therapeutics Ltd's website is nerretherapeutics.com
Nerre Therapeutics Ltd's LinkedIn profile is https://uk.linkedin.com/company/nerre-therapeutics-ltd
Nerre Therapeutics Ltd has
9 employees.
View email and phone details for 9
employees at Nerre Therapeutics Ltd.
Nerre Therapeutics Ltd's industry is
Biotechnology Research
Nerre Therapeutics Ltd's top competitors are
Apexomic,
Bradford-Renduchintala Enterprise Ecosystem,
Akari Therapeutics, Plc,
Neobe Therapeutics,
Nrg Therapeutics,
Ossianix,
Nucana Plc,
Stevenage Bioscience Catalyst,
Bioinnovation Institute,
Loqus23 Therapeutics Ltd.
Nerre Therapeutics Ltd's support email address is info@nerretherapeutics.com
Nerre Therapeutics Ltd's categories are Biotechnology Research
Nerre Therapeutics Ltd's founding year is 2012
